Skip to main content

Table 6 Circulating biomarkers other than carbohydrate antigens for recognizing malignant IPMNs. Cutoff values were annotated in brackets. The number of malignant IPMN patients and total IPMN patients were displayed in column investigation sample size

From: Carbohydrate antigen 125 supplements carbohydrate antigen 19-9 for the prediction of invasive intraductal papillary mucinous neoplasms of the pancreas

 

Serological biomarkers

Investigation sample size

Sensitivity

Specificity

Reference (PMID)

Classical biomarker

Fibrinogen (4.71 g/L)

21/73

42.9%

88.5%

28131667

Serum pancreatic enzymes (lipase and amylase)

54/203

Cutoff values did not determined

25239347

42/142

27394653

Extracellular vesicle

MUC5 (10, DEST assay)

34/123

100%

82%

33301777

MicroRNA

miR-223 (125.0 atto M)

28/36

82.4%

62.9%

25819175

miR-1290

16/20

Cutoff value did not determined (AUC = 0.82)

23697990

miR-483-3p and miR-21

32/44

Cutoff values did not determined (AUC = 0.703 and 0.603, respectively)

25384963

Antibody

CEA (5.0 ng/ml)

CA9-9 (37 U/ml)

p53 antibody (1.3 U/ml)

73/111

38.4%

81.6%

32541631

Antibodies to Fusobacterium nucleatum

46/91

Cutoff value did not determined

32983143

  1. DEST digital extracellular vesicle screening technique